|
|
 |
|
Total Number of Holdings (excluding cash): 50
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
2,475 |
$2,734,875.00 |
7.80% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
21,021 |
$2,495,613.12 |
7.12% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
11,216 |
$2,441,947.52 |
6.97% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
41,733 |
$2,386,292.94 |
6.81% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
10,477 |
$2,360,782.41 |
6.73% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
87,169 |
$1,417,367.94 |
4.04% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
6,784 |
$1,329,664.00 |
3.79% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
47,068 |
$1,232,240.24 |
3.52% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
8,738 |
$1,174,649.34 |
3.35% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
2,620 |
$1,172,554.80 |
3.34% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
3,353 |
$1,129,256.87 |
3.22% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Pharmaceuticals |
5,678 |
$1,117,430.40 |
3.19% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
1,920 |
$1,069,094.40 |
3.05% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
1,665 |
$1,023,608.70 |
2.92% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
3,943 |
$932,480.07 |
2.66% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
8,062 |
$779,917.88 |
2.22% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
9,927 |
$771,228.63 |
2.20% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
4,308 |
$702,031.68 |
2.00% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
12,111 |
$611,363.28 |
1.74% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
3,099 |
$490,571.70 |
1.40% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
6,420 |
$474,117.00 |
1.35% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
1,019 |
$455,605.09 |
1.30% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
2,505 |
$452,678.55 |
1.29% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
7,443 |
$426,409.47 |
1.22% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
9,873 |
$416,541.87 |
1.19% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
5,896 |
$392,319.84 |
1.12% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
12,871 |
$306,973.35 |
0.88% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
4,162 |
$305,907.00 |
0.87% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
6,008 |
$283,457.44 |
0.81% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
3,815 |
$255,109.05 |
0.73% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
1,906 |
$247,189.14 |
0.71% |
| Catalyst Pharmaceuticals, Inc. |
CPRX |
14888U101 |
Biotechnology |
7,756 |
$242,219.88 |
0.69% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
3,076 |
$239,651.16 |
0.68% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
8,787 |
$222,662.58 |
0.64% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
5,948 |
$225,667.12 |
0.64% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
7,765 |
$219,788.33 |
0.63% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
902 |
$209,227.92 |
0.60% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
15,297 |
$201,461.49 |
0.57% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
649 |
$200,560.47 |
0.57% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
1,940 |
$196,910.00 |
0.56% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
1,944 |
$193,544.64 |
0.55% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
6,185 |
$185,488.15 |
0.53% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
2,205 |
$168,682.50 |
0.48% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
538 |
$162,465.24 |
0.46% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
1,960 |
$159,583.20 |
0.46% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
7,288 |
$157,858.08 |
0.45% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
3,341 |
$157,661.79 |
0.45% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
3,271 |
$151,054.78 |
0.43% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
6,637 |
$142,430.02 |
0.41% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
2,371 |
$140,837.40 |
0.40% |
| US Dollar |
$USD |
|
Other |
88,240 |
$88,240.06 |
0.25% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|